# Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection

> **NCT03555526** · PHASE4 · UNKNOWN · sponsor: **National Taiwan University Hospital** · enrollment: 320 (estimated)

## Conditions studied

- H Pylori Infection

## Interventions

- **DRUG:** Esomeprazole 40mg
- **DRUG:** Amoxicillin
- **DRUG:** metronidazole
- **DRUG:** Levofloxacin 500mg
- **DRUG:** Clarithromycin ER
- **DRUG:** Esomeprazole 40mg
- **DRUG:** Dibismuth trioxide
- **DRUG:** metronidazole
- **DRUG:** tetracycline

## Key facts

- **NCT ID:** NCT03555526
- **Lead sponsor:** National Taiwan University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-12-15
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2018-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03555526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03555526, "Genotypic Resistance Guided Therapy for Refractory H. Pylori Infection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03555526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*